Published in Cancer on April 01, 2008
Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer. Oncologist (2011) 0.98
The importance of supportive care in optimizing treatment outcomes of patients with advanced prostate cancer. Oncologist (2012) 0.84
Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review. Support Care Cancer (2013) 0.81
Dermatological adverse events with taxane chemotherapy. Eur J Dermatol (2016) 0.81
Supportive cryotherapy: a review from head to toe. J Pain Symptom Manage (2013) 0.77
The effectiveness of regional cooling for paclitaxel-induced peripheral neuropathy. J Pharm Health Care Sci (2016) 0.75
Cryotherapy for docetaxel-induced hand and nail toxicity: randomised control trial. Support Care Cancer (2013) 0.75
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 39.39
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet (2008) 19.58
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 13.52
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol (2009) 6.86
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol (2009) 5.05
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol (2013) 4.91
Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. Eur Urol (2008) 3.06
Therapeutic dendritic-cell vaccine for simian AIDS. Nat Med (2002) 2.76
Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med (2004) 2.64
Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. J Clin Oncol (2012) 2.56
Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol (2005) 2.50
Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Eur Urol (2011) 2.10
Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients. Pediatrics (2003) 1.91
Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol (2007) 1.90
Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. Lancet Oncol (2007) 1.86
Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. J Clin Oncol (2013) 1.74
Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer (2007) 1.73
Platelet microparticles: a potential predictive factor of survival in hormone-refractory prostate cancer patients treated with docetaxel-based chemotherapy. Eur Urol (2008) 1.66
Metastatic renal cell carcinoma: relationship between initial metastasis hypoxia, change after 1 month's sunitinib, and therapeutic response: an 18F-fluoromisonidazole PET/CT study. J Nucl Med (2011) 1.62
The biological meaning of anti-HBC positive result in blood donors: relation to HBV-DNA and to other serological markers. Rev Inst Med Trop Sao Paulo (2003) 1.56
Completely resected non-small cell lung cancer: reconsidering prognostic value and significance of N2 metastases. Ann Thorac Surg (2007) 1.54
Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst (2008) 1.53
The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells. Blood (2008) 1.48
Phase I and pharmacokinetic study of IV vinflunine in combination with gemcitabine for treatment of advanced non-small cell lung cancer in Chemonaive patients. J Thorac Oncol (2011) 1.43
A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J Immunother (2010) 1.40
Predictive and discriminating three-risk-group prognostic scoring system for staging Hodgkin lymphomas. Cancer (2007) 1.40
Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med (2008) 1.36
Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer (2010) 1.35
Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. Clin Cancer Res (2013) 1.33
A Fluorospot assay to detect single T lymphocytes simultaneously producing multiple cytokines. J Immunol Methods (2003) 1.29
Transcription factor E3 and transcription factor EB renal cell carcinomas: clinical features, biological behavior and prognostic factors. J Urol (2010) 1.16
Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941. J Urol (2007) 1.13
Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol (2005) 1.13
Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study. BJU Int (2010) 1.13
Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities. Invest New Drugs (2012) 1.13
Collecting duct carcinoma of the kidney: a clinicopathological study of 9 cases. J Urol (2003) 1.09
Epidermal growth factor receptor (EGFR) and KRAS mutations during chemotherapy plus anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer. Cancer Chemother Pharmacol (2013) 1.09
Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT. Radiology (2010) 1.09
A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings. Cancer Immunol Immunother (2010) 1.08
Phase II study of lonidamine and diazepam in the treatment of recurrent glioblastoma multiforme. J Neurooncol (2003) 1.06
Outcome of suprarenal localized masses diagnosed during the perinatal period: a retrospective multicenter study. Cancer (2002) 1.05
Molecular tracing of sexual HIV Type 1 transmission in the southwest border of China. AIDS Res Hum Retroviruses (2008) 1.04
Molecular epidemiological tracing of HIV-1 outbreaks in Hainan island of southern China. AIDS (2009) 1.03
First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity. J Transl Med (2010) 1.01
Three irradiation treatment options including radiosurgery for brain metastases from primary lung cancer. Lung Cancer (2003) 1.00
Hormone escape is associated with genomic instability in a human prostate cancer model. Int J Cancer (2009) 1.00
Current and emerging treatment modalities for metastatic castration-resistant prostate cancer. BJU Int (2011) 0.99
Induction of CD8+ regulatory T cells protects macaques against SIV challenge. Cell Rep (2012) 0.99
Meta-analysis of randomised trials comparing gemcitabine-based doublets versus gemcitabine alone in patients with advanced and metastatic pancreatic cancer. Drugs Aging (2007) 0.98
Chemotherapy for the treatment of malignant peripheral nerve sheath tumors in neurofibromatosis 1: a 10-year institutional review. Orphanet J Rare Dis (2013) 0.98
VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis. Acta Oncol (2013) 0.98
What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel? BJU Int (2009) 0.98
Dominant effects of CCR2-CCR5 haplotypes in HIV-1 disease progression. J Acquir Immune Defic Syndr (2004) 0.98
Lung cancer and renal insufficiency: prevalence and anticancer drug issues. Lung (2008) 0.98
Salvage therapy with bevacizumab-sunitinib combination after failure of sunitinib alone for metastatic renal cell carcinoma: a case series. Eur Urol (2009) 0.97
Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues. Breast Cancer Res Treat (2008) 0.97
Optimisation of the tumour response threshold in patients treated with everolimus for metastatic renal cell carcinoma: analysis of response and progression-free survival in the RECORD-1 study. Eur J Cancer (2012) 0.94
Multiple lung cancers prognosis: what about histology? Ann Thorac Surg (2008) 0.93
Screening for psychological distress in two French cancer centers: feasibility and performance of the adapted distress thermometer. Palliat Support Care (2008) 0.93
Distinct responses of xenografted gliomas to different alkylating agents are related to histology and genetic alterations. Cancer Res (2004) 0.92
Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib. BJU Int (2014) 0.91
Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib. Acta Oncol (2014) 0.90
Prostate-specific antigen kinetics in localized and advanced prostate cancer. BJU Int (2009) 0.90
Comprehensive analysis of HLA-DR- and HLA-DP4-restricted CD4+ T cell response specific for the tumor-shared antigen survivin in healthy donors and cancer patients. J Immunol (2008) 0.89
Drug management of prostate cancer: prevalence and consequences of renal insufficiency. Clin Genitourin Cancer (2009) 0.88
Evolution of renal function in patients treated with antiangiogenics after nephrectomy for renal cell carcinoma. Urol Oncol (2009) 0.88
Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma. Expert Rev Anticancer Ther (2009) 0.87
Fifteen-year secondary leukaemia risk observed in 761 patients with Hodgkin's disease prospectively treated by MOPP or ABVD chemotherapy plus high-dose irradiation. Br J Haematol (2002) 0.87
New insights into the management of renal cell cancer. Oncology (2012) 0.87
[Cabazitaxel for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: the TROPIC study in France]. Bull Cancer (2012) 0.87
Expression of genes involved in chemoresistance, proliferation and apoptosis in clinical samples of renal cell carcinoma and correlation with clinical outcome. Anticancer Res (2002) 0.86
Renal insufficiency and anticancer drugs in elderly cancer patients: a subgroup analysis of the IRMA study. Crit Rev Oncol Hematol (2008) 0.86
Variability of bio-clinical parameters in Chinese-origin Rhesus macaques infected with simian immunodeficiency virus: a nonhuman primate AIDS model. PLoS One (2011) 0.86
Renal malacoplakia: Case report of a differential diagnosis for renal cell carcinoma. Am J Case Rep (2012) 0.85
Olecranon bursitis in patients treated with sunitinib for renal cell carcinoma. Med Oncol (2009) 0.85
A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial. Eur J Cancer (2011) 0.85
Randomized study of intravenous versus subcutaneous interleukin-2, and IFNalpha in patients with good prognosis metastatic renal cancer. Clin Cancer Res (2008) 0.85
Molecular epidemiology of human immunodeficiency virus type 1 in Guangdong province of southern China. PLoS One (2012) 0.85